These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26681760)

  • 1. Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.
    Jonsdottir G; Lund SH; Björkholm M; Turesson I; Wahlin A; Mailankody S; Blimark C; Hultcrantz M; Porwit A; Landgren O; Kristinsson SY
    Haematologica; 2016 Apr; 101(4):e145-8. PubMed ID: 26681760
    [No Abstract]   [Full Text] [Related]  

  • 2. Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.
    Reddi DM; Lu CM; Fedoriw G; Liu YC; Wang FF; Ely S; Boswell EL; Louissaint A; Arcasoy MO; Goodman BK; Wang E
    Am J Clin Pathol; 2012 Dec; 138(6):855-66. PubMed ID: 23161720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma.
    Duong VH; Holtzman NG; Koka R; Singh ZN; Zou Y; Emadi A; Rapoport AP; Kocoglu MH; Baer MR; Badros AZ
    Leuk Lymphoma; 2019 Dec; 60(14):3577-3580. PubMed ID: 31282234
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries.
    Chen T; Fallah M; Brenner H; Jansen L; Mai EK; Castro FA; Katalinic A; Emrich K; Holleczek B; Geiss K; Eberle A; Sundquist K; Hemminki K;
    Sci Rep; 2016 Feb; 6():22084. PubMed ID: 26908235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
    Jonsdottir G; Björkholm M; Turesson I; Hultcrantz M; Diamond B; Porwit A; Landgren O; Kristinsson SY
    Eur J Haematol; 2021 Aug; 107(2):275-282. PubMed ID: 33966293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment.
    Sevcikova K; Zhuang Z; Garcia-Manero G; Alvarez RH; Kantarjian HM; Mego M; Albarracin C; Tang G; Strom SS; Medeiros LJ; Hortobagyi GN; Reuben JM; Khoury JD
    Leukemia; 2016 Jan; 30(1):242-7. PubMed ID: 25975189
    [No Abstract]   [Full Text] [Related]  

  • 7. Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma.
    Thakral B; Muzzafar T
    Blood; 2017 Jul; 130(2):231. PubMed ID: 28705862
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
    Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
    Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.
    Hulegårdh E; Nilsson C; Lazarevic V; Garelius H; Antunovic P; Rangert Derolf Å; Möllgård L; Uggla B; Wennström L; Wahlin A; Höglund M; Juliusson G; Stockelberg D; Lehmann S
    Am J Hematol; 2015 Mar; 90(3):208-14. PubMed ID: 25421221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
    Bally C; Thépot S; Quesnel B; Vey N; Dreyfus F; Fadlallah J; Turlure P; de Botton S; Dartigeas C; de Renzis B; Itzykson R; Fenaux P; Adès L
    Leuk Res; 2013 Jun; 37(6):637-40. PubMed ID: 23499498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
    Broijl A; Kersten MJ; Alemayehu WG; Levin MD; de Weerdt O; Vellenga E; Meijer E; Wittebol S; Tanis BC; Cornelisse PB; Stevens-Kroef M; Bos GM; Wijermans PW; Lokhorst H; Sonneveld P
    Haematologica; 2016 Apr; 101(4):e149-52. PubMed ID: 26659914
    [No Abstract]   [Full Text] [Related]  

  • 12. Myeloma and second primary cancers.
    Landgren O; Thomas A; Mailankody S
    N Engl J Med; 2011 Dec; 365(23):2241-2. PubMed ID: 22150057
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and
    Martin-Cabrera P; Jeromin S; Perglerovà K; Haferlach C; Kern W; Haferlach T
    Haematologica; 2017 Apr; 102(4):e125-e128. PubMed ID: 28057736
    [No Abstract]   [Full Text] [Related]  

  • 14. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
    Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
    J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.
    Sasaki K; Jabbour E; Cortes J; Kadia T; Garcia-Manero G; Borthakur G; Jain P; Pierce S; Daver N; Takahashi K; O'Brien S; Kantarjian H; Ravandi F
    Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):616-624. PubMed ID: 27601000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias.
    Sridharan A; Schinke CD; Georgiev G; Da Silva Ferreira M; Thiruthuvanathan V; MacArthur I; Bhagat TD; Choudhary GS; Aluri S; Chen J; Pradhan K; Xia Y; Panjikaran M; Sims G; Bhagat CK; Bender R; Keeler L; Graber A; Heuck C; Fletcher FA; Alapat D; Weinhold N; Johnson SK; Wickrema A; Barlogie B; Morgan GJ; Shastri A; Steidl U; Will B; Verma A
    Blood Adv; 2019 Dec; 3(23):3962-3967. PubMed ID: 31805192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
    Bigenwald C; Harel S; Chevignon F; Roos-Weil D; Bernard OA; Amorim S; Brice P; Adès L; Nloga AM; Sébert M; Braun T; Eclache V; Thieblemont C; Fenaux P
    Br J Haematol; 2018 Jan; 180(2):304-308. PubMed ID: 27662562
    [No Abstract]   [Full Text] [Related]  

  • 18. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
    Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
    Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fatal Clostridium infection in an allogeneic stem cell transplant recipient.
    Jain M; Titanji R; Rapoport AP; Wang W; Gocke C; Cross A; Akpek G
    Bone Marrow Transplant; 2005 Sep; 36(5):455-7. PubMed ID: 15995716
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
    Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E
    Br J Haematol; 2007 Aug; 138(4):555-7. PubMed ID: 17593249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.